Medical Care Technologies, Inc. (OTC PINK:MDCE) Advances Melanoma Scan Beta Through Comprehensive AI Model Optimization Using Gold-Standard Datasets

By leveraging leading public benchmark datasets, the Company has executed a rigorous, methodical development cycle designed to deliver robust, high-performing AI capabilities. These advancements underscore MDCE's commitment to innovation in AI imaging technologies and highlight significant potential within the rapidly expanding preventive wellness and digital health markets.

MDCE's Six-Phase AI Model Optimization Protocol:

Phase 1: Data Acquisition & Curation - Sourcing high-quality dermoscopic images from premier public resources, including the HAM10000 dataset, extensive ISIC Archive collections (such as BCN20000 and SLICE-3D), and TCIA melanoma cohorts.

Phase 2: Preprocessing & Augmentation - Applying advanced techniques such as rotations, color corrections, and synthetic variations to enhance model robustness across diverse conditions.

Phase 3: Core Model Training - Leveraging state-of-the-art convolutional neural networks and transformer-based architectures to build powerful computer vision foundations.

Phase 4: Iterative Optimization - Conducting hyperparameter tuning and adversarial training to maximize performance and resilience.

Phase 5: Multi-Scenario Validation - Rigorous testing across diverse demographics, skin tones, lighting conditions, and lesion presentations to ensure real-world applicability.

Phase 6: Performance Benchmarking & Refinement - Achieving results slightly exceeding established industry benchmarks for AI-powered skin lesion analysis tools, while maintaining superior workflow efficiency.

"This comprehensive six-phase approach reflects the depth of our technical execution and strengthens the foundation for future growth," said Marshall Perkins, CEO of Medical Care Technologies. "We are excited by the momentum in our AI initiatives and their potential to contribute to our diversified technology portfolio as we pursue opportunities in preventive wellness."

The MDCE Melanoma Scan Beta platform is being developed as an image organization and monitoring system intended to support longitudinal skin health tracking and preventative wellness awareness. It remains in beta-stage development, has not received regulatory clearance, and is not intended to diagnose, treat, cure, or prevent any disease or medical condition, nor to replace professional medical advice or evaluation by a qualified healthcare provider.